Dr. Hedy Lee KindlerFocus: Pleural & Peritoneal Mesothelioma
University of Chicago Medicine
5758 S. Maryland Ave
As one of the top mesothelioma specialists in the United States, Dr. Kindler has been a leader in developing treatment for mesothelioma patients.
About Dr. Kindler
Hedy Lee Kindler, M.D., is a cancer expert with years of experience studying and treating mesothelioma. She sees more than 100 mesothelioma cases a year and continues to bring on new patients with the hopes of helping as many people as possible. Many of her patients come from all over the world to seek her experience and guidance.
Medical Degree and Residency
MD State University of New York Buffalo, 1989. Dr. Kindler completed residency at UCLA Medical Center Internal Medicine from 1989-1991.
Assistant Professor of Medicine University of Chicago Medical Center
A champion for mesothelioma recovery, Dr. Kindler has traveled extensively, proving theories and treatments for these conditions to medical experts worldwide. She is frequently invited to speak on the latest findings and treatments available in asbestos-related diseases.
Although her emphasis is on mesothelioma recovery and treatment, Dr. Kindler also specializes in the medical treatment of pancreatic cancer and gastrointestinal stromal tumors.
Dr. Kindler’s Accomplishments
Kindler is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, the International Mesothelioma Interest Group, and the Mesothelioma Applied Research Foundation. Additionally, Dr. Kindler is a two-term (2006-2010) past president of the International Mesothelioma Interest Group and is an associate editor of the medical journal, Lung Cancer.
Get Connected To Dr. Hedy Lee Kindler
Why Choose Dr. Kindler?
- Oversees various cutting edge clinical trials
- Former President of International Mesothelioma Interest Group
- Has treated various survivors and extended life
Dr. Kindler's Clinical Research
As Dr. Kindler has a personal interest in the treatment of mesothelioma, much of her research is focused on novel treatments. This research holds potential to not only improve the survival times of patients but also lead to more personalized treatment options.
“The Role of Gemcitabine in the Treatment of Mesothelioma”
Dr. Kindler published this article back in 2002 to discuss the efficacy of the chemotherapy drug, gemcitabine, as a single agent or in combination with a platinum-based chemotherapy drug. What makes the article interesting is that Dr. Kindler suggests other roles the drug may play. The most notable role she suggests in the study is gemcitabine in combination “with other cytotoxic chemotherapy agents such as pemetrexed or vinorelbine, or adding novel cytostatic agents…such as bevacizumab.”
“Moving Beyond Chemotherapy”
Following her article in 2002, Dr. Kindler published an article 2 years later titled, “Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.” The study evaluated the efficacy of novel drugs such as bevacizumab, which work by interfering with the signaling pathways that affect mesothelioma cell growth. Years later, this research has shown to have a significant survival benefit to mesothelioma patients.
Many patients have opened up new treatment options and even reached remission by enrolling in clinical trials. Get access to new mesothelioma treatments by enrolling in clinical trials.
Learn how survivors have beat the odds by enrolling in clinical trials and seeing specialists like Dr. Kindler in our free Mesothelioma Survivors Guide.